CAPR Stock Jumps As Street Hikes Price Targets Into FDA Catalyst

Capricor Therapeutics Inc. stocks have been trading up by 13.28 percent after promising positive news boosted investor confidence.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading CAPR

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways

Street upgrades and sharp price target hikes have pushed Capricor Therapeutics (CAPR) firmly onto traders’ radar ahead of a key FDA decision.
B. Riley boosted its rating to Buy and lifted its CAPR target from $5 to $21, tying the call to November 22 FDA risk/reward and upcoming data on deramiocel.
Piper Sandler turned Overweight on CAPR, raising its target from $2 to $25 and flagging a favorable setup into the extended FDA action date.
CAPR shares popped roughly 4%–5% on each upgrade, confirming that analyst moves are driving real trading momentum in the name.
A new Schedule 13G revealed a significant passive stake in CAPR, signaling rising institutional interest alongside the bullish research calls.

Live Update At 07:47:12 EDT: On Wednesday, September 30, 2026 Capricor Therapeutics Inc. stock [NASDAQ: CAPR] is trending up by 13.28%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Capricor Therapeutics (CAPR) trades like a classic catalyst biotech — choppy but liquid, with big moves around news. The recent multi-day chart shows CAPR mostly oscillating between $8.30 and $9.40, with repeated failures to hold above the $9.30–$9.50 area. That tells traders the stock is building a base but still battling selling pressure on pops.

Intraday, the 5‑minute action shows CAPR spiking above $12 early, then fading back toward the high‑$9s. That is textbook momentum behavior after a news-driven run: early chasers push it up, then profit-taking and late longs create a slow bleed lower. For active traders, that means both upside opportunity and real downside risk if you chase strength.

More Breaking News

Fundamentally, CAPR is still a development‑stage biotech. The company’s latest quarterly numbers show negative net income of about $40.7M and an operating cash burn north of $31M, so it is not generating profits. Returns on equity and assets are steeply negative, reflecting heavy R&D spending. On the positive side, Capricor carries minimal debt, sports a strong current ratio around 7.4, and holds sizable cash and short‑term investments, giving it room to fund operations through near‑term catalysts.

Why Traders Are Watching CAPR Into The FDA Decision

CAPR is drawing fresh attention because the story has shifted from “biotech grinder” to “event-driven momentum play.” The main catalyst is deramiocel, Capricor Therapeutics’ lead therapy, heading into a November 22, 2026 FDA action date. B. Riley lit the fuse on 2026/09/14, upgrading CAPR to Buy from Neutral and blasting its price target from $5 to $21. They framed CAPR as a favorable risk/reward setup into that November decision, and they also pointed to possible positive open-label extension data at the World Muscle Society conference on 2026/10/03.

That kind of call matters. Traders watch when a shop takes a target from $5 to $21 — it signals the Street is re‑rating the story, not just tweaking a model. CAPR responded with a roughly 5.1% jump after the B. Riley note hit, confirming that funds and short‑term traders were paying attention.

This wasn’t a one‑off. Back on 2026/09/01, Piper Sandler also upgraded Capricor Therapeutics to Overweight from Neutral and rocketed its target from $2 to $25, again citing an attractive risk/reward profile into the extended November 22 FDA date. CAPR shares climbed about 4%–4.5% on that news. When two separate firms both move from neutral stances to bullish and hike targets by double‑digits, momentum traders tend to swarm.

Layer on top the FactSet data showing an average Overweight rating and a mean price target around $31.78 — even higher than those new targets — and you have a name where Street expectations are clearly skewed to the upside. Add the Schedule 13G disclosing a significant passive stake in CAPR, and the message is clear: analysts and larger players are positioning ahead of the same binary event. That combination is exactly what short‑term traders look for when they scan for high‑volatility setups.

Conclusion

For active traders, CAPR is now a catalyst‑driven story with real juice behind it. The stock has already shown it can move 4%–5% in a session off a single upgrade, and both B. Riley and Piper Sandler have re‑framed Capricor Therapeutics as a potential upside play into the November 22 FDA action date on deramiocel. The broader Street, with a mean target near $31.78, is even more optimistic, while a new Schedule 13G filer adds another layer of confidence that bigger money is involved.

At the same time, the financials remind everyone what this really is: a loss‑making biotech burning cash to chase a big outcome. CAPR’s negative earnings, heavy R&D spend, and volatile intraday tape all underline the need for strict risk management. If the deramiocel read‑throughs or FDA decision disappoint, the same leverage that helps on the way up can cut just as hard on the way down.

This is where discipline matters. As Tim Sykes likes to say, “The market rewards prepared traders, not hopeful gamblers.” As Tim Bohen, lead trainer with StocksToTrade says, “Time and experience have taught me that missed opportunities are part of the game. There’s always another setup around the corner.” Traders studying CAPR should treat it as a textbook event‑catalyst setup — map the key dates, respect the volatility, and always have a plan for cutting losses fast. This article is for educational and research purposes only and is not investment advice.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!